Form 4: Caribou Biosciences CFO Sriram Ryali Reports Transaction in Company Stock
SEC Form 4 Filing
Chief Financial Officer Sriram Ryali reports acquiring 17,360 shares of Caribou Biosciences at $1.42 per share on January 29, 2025.
Summary
- On January 29, 2025, Sriram Ryali, the Chief Financial Officer of Caribou Biosciences, Inc., acquired 17,360 shares of common stock.
- The purchase price was $1.42 per share.
- Following the transaction, Mr. Ryali directly owns 17,360 shares of Caribou Biosciences.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock transaction by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with company performance.
Stakeholder Impact
- The transaction provides shareholders with insight into the actions of a key executive.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | Date of transaction: Sriram Ryali acquired 17,360 shares of Caribou Biosciences common stock. |
| 01/30/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.